| Literature DB >> 18676346 |
Eero Honkanen1, Leena Kauppila, Björn Wikström, Pieter L Rensma, Jean-Marie Krzesinski, Knut Aasarod, Francis Verbeke, Per Bruno Jensen, Pierre Mattelaer, Birgitte Volck.
Abstract
BACKGROUND: Patients with chronic kidney disease stage 5 have a high prevalence of vascular calcification, but the specific anatomical distribution and severity of abdominal aortic calcification (AAC), in contrast to coronary calcification, is less well documented. AAC may be recorded using plain radiographs. The present report is an analysis of baseline data on AAC in patients enrolled in the CORD (Calcification Outcome in Renal Disease) study.Entities:
Mesh:
Year: 2008 PMID: 18676346 PMCID: PMC2639067 DOI: 10.1093/ndt/gfn403
Source DB: PubMed Journal: Nephrol Dial Transplant ISSN: 0931-0509 Impact factor: 5.992
Fig. 1Abdominal aorta calcification (AAC) scoring. Grading of calcification was assessed at the anterior and the posterior walls of the abdominal aorta adjacent to vertebrae L1–L4 and the composite score determined.
Baseline patient characteristics
| Characteristic | Value |
|---|---|
| Mean (range) age (years) | 61.4 (19–89) |
| Gender (%) | |
| Male | 60.8 |
| Female | 39.2 |
| Mean (range) mass index (kg/m2) | 25.1 (15.4–46.4) |
| Diabetes (%) | |
| With | 22.9 |
| Without | 77.1 |
| Tobacco use (%) | |
| Yes | 18.5 |
| No | 81.5 |
| History of cardiovascular disease (%) | |
| Yes | 43.7 |
| No | 56.3 |
| Type of dialysis (%) | |
| Haemodialysis | 83.9 |
| Peritoneal dialysis | 16.1 |
| Mean (range) duration of dialysis (months) | 38.2 (3–363) |
Blood pressure and laboratory values
| Parameter | Mean (range) |
|---|---|
| Systolic blood pressure (mmHg) | 146 (72–218) |
| Diastolic blood pressure (mmHg) | 79 (30–141) |
| Pulse pressure (mmHg) | 67 (17–131) |
| Serum calcium (mmol/l) | 2.4 (1.5–3.0) |
| Serum phosphorus (mmol/l) | 1.7 (0.4–3.4) |
| Calcium phosphorus product (mmol2/l2) | 4.0 (0.9–8.3) |
| S-PTH int (ng/l) | 281 (1.0–2505) |
| Serum C-reactive protein (mg/l) | 11 (0–253) |
| Total serum cholesterol (mmol/l) | 4.2 (1.7–9.0) |
| Serum LDL cholesterol (mmol/l) | 2.2 (0.01–6.4) |
| Serum HDL cholesterol (mmol/l) | 1.3 (0.5–3.7) |
| Serum triglycerides (mmol/l) | 1.8 (0.4–17.0) |
S-PTH int = intact parathyroid hormone, LDL = low-density lipoprotein, HDL = high-density lipoprotein.
Current medication of the study population
| Agent | Percentage of patients | Mean (range) dose (mg) |
|---|---|---|
| Phosphate binders | ||
| Calcium containing | 73 | 2026 (200–10 000) |
| Aluminium containing | 4 | 1734 (400–6000) |
| Sevelamer | 48 | 4866 (800–16 000) |
| Vitamin D analogues | 52 | |
| Oral anticoagulants | 14 | |
| Statins | 35 | |
| Angiotensin-converting enzyme inhibitors or angiotensin II receptor blocking agents | 39 | |
| Beta blocking agents | 48 | |
| Calcium channel blocking agents | 27 | |
| Erythropoiesis stimulating agents | 93 |
Fig. 2Number of aortic segments affected by calcific deposits.
Fig. 3Abdominal aortic calcification (AAC) scores in segments L1–L4 (n = 933; P < 0.0001).
Fig. 4Abdominal aortic calcification (AAC) scores in individual patients in relation to their age.
Fig. 5Plain X-ray of (A) a 59-year-old patient with abundant abdominal aortic calcification (AAC = 21) and (B) a 73-year-old patient with no calcific deposits in the abdominal aorta (AAC = 0).